Sector Alpha Week of 2026-09-17
Not SEBI Registered !! Not Investment advice !!
Sector Alpha — machine-written from the numbers · Data as of 2026-09-17

BillionToOne, Inc.

BLLN
Healthcare · Diagnostics & Research

BillionToOne, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.

The price is between stages. Underneath, the last four quarters read improving. What settles it: the next one or two quarters of delivery.

Price
$104
+3.6% 1Y
P/E
134.7×
vs its own history
Revenue (Mar 26)
$0.1 B
+83.3% YoY
Profit (Mar 26)
$0.0 B
Operating margin
18.2%
+18.2 pp YoY
ROE
11%
FY25
ROIC
35.2%
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

BillionToOne, Inc. trades at $104, between stages. That is +9.2% against its own 200-day average. It sits at 50% of a 52-week range of $69 to $139. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (4 weeks and counting).

Today the stock is between stages. At $104 it trades +9.2% versus its 200-day average and sits at 50% of its 52-week range ($69–$139).

Sep 26: $104 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 1-year window.
+9.2% versus the 200-day line, week — of stage —
Price50-day avg200-day avg
$144$124$104$83.7$63.6$$104$95Nov 25Jan 26Apr 26Jun 26Sep 26
$144$124$104$83.7$63.6$$104$95Nov 25Apr 26Sep 26
Beating or trailing, week by week since 2025 Each cell is one week from 2025 to now (46 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Nov 25Sep 26

Against the market, two honest reads. Cumulative: over the last 11 months the stock moved +4% while the S&P 500 moved +12% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (4 weeks and counting; last ahead the week of 2026-08-21) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

BillionToOne, Inc. trades at 134.7× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 134.7× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E
134.7×
too little history to rank
PEG
2.12
derived from 3-year earnings growth

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: No read

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

BillionToOne, Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 6 quarters across 1 curve, on partial evidence.

Growth, year by year: revenue +106.7% in FY25 Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoY
115%113%111%108%106%%106.7%FY23FY24FY25
115%113%111%108%106%%106.7%FY23FY24FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. Where the trailing-twelve-month history is short, the curve falls back to single-quarter year-on-year growth — noisier, and the classifier smooths and caps base-effect spikes before reading. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from
Revenue
102%95%88%80%73%%83.3%Mar 24Mar 25Mar 26
102%95%88%80%73%%83.3%Mar 24Mar 25Mar 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
11%3.8%−3.0%−9.8%−17%%8.8%Mar 24Sep 24Mar 25Sep 25Mar 26
11%3.8%−3.0%−9.8%−17%%8.8%Mar 24Mar 25Mar 26
ROCE
Rising
latest 8.8% · span −14.8%–8.8%

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+106.7%
Stock price+3.6%
Revenue YoY (Mar 26)
+83.3%
latest quarter vs a year ago
Revenue 10y
110.4%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

54.6/100 — rank 24 of 30 in Diagnostics & Research · 31% evidence confidence · provisional, ranked below fully-evidenced peers

BillionToOne, Inc. scores 54.6 out of 100 against the 30 companies it is compared with in Diagnostics & Research, ranking 24. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 23 + 12.3 + 9.3 + 10 = 54.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

BillionToOne, Inc. reported $0.1 B of revenue in the Mar 26 quarter, +83.3% year on year. That is the 5th straight quarter of year-on-year growth. Over 2 years it has compounded at 110.4% a year. The last full year, FY25, came in at $0.3 B. The last four reported quarters add to $0.4 B.

FY25 revenue came in at $0.3 B (+106.7% on the year), capping 2 years at 110.4% compound. The latest quarter (Mar 26) printed $0.1 B, +83.3% year on year — the 5th consecutive quarter of year-over-year growth.

FY25 revenue $0.3 B (+106.7% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 3-year window. A bar is red when it is lower than the year before.
110.4% a year over 2 years
RevenueYoY growth
0.33115%0.25113%0.17111%0.08108%0.00106%$ B%$0B106.7%FY23FY24FY25
0.33115%0.25113%0.17111%0.08108%0.00106%$ B%$0B106.7%FY23FY24FY25
Mar 26: $0.1 B (+83.3% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
5th straight quarter of growth
Revenue (quarterly)YoY growth
0.12102%0.0995%0.0688%0.0380%0.0073%$ B%$0B83.3%Mar 24Mar 25Mar 26
0.12102%0.0995%0.0688%0.0380%0.0073%$ B%$0B83.3%Mar 24Mar 25Mar 26

Pace check: the last four quarters averaged +89.6% growth against the decade's 110.4% — the current year is running slower than its own long-run rate.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

BillionToOne, Inc.'s operating margin is 18.2% in the Mar 26 quarter, +18.2 percentage points against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged −100.0% to 6.5%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 18.2%, +18.2 pp against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged −100.0%–6.5%.

Why the margin moved: operating margin went +18.2 pp year on year while gross margin went +6.0 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

FY25: 6.5% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 3-year window.
within a −100.0–6.5% band over 3 years
operating marginYoY change (pp)
15%69%−16%61%−47%53%−78%45%−109%38%%%6.5%39.8%FY23FY24FY25
15%69%−16%61%−47%53%−78%45%−109%38%%%6.5%39.8%FY23FY24FY25
Mar 26: 18.2% operating margin (+18.2 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
22%39%7.4%33%−7.5%28%−22%22%−37%17%%%18.2%18.2%Mar 24Mar 25Mar 26
22%39%7.4%33%−7.5%28%−22%22%−37%17%%%18.2%18.2%Mar 24Mar 25Mar 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

BillionToOne, Inc. earned $0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.0 B. That is 18.2% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 4 of the last 9 reported quarters were loss-making.

Mar 26 profit was $0.0 B, null year on year. On the full year, FY25 printed $0.0 B (null).

FY25 profit $0.0 B (null YoY) Net profit bars, $ B (left); YoY growth-% line (right). 3-year window. A bar is red when it is lower than the year before.
Net profit
0.02−0.01−0.03−0.05−0.08$ B$0BFY23FY24FY25
0.02−0.01−0.03−0.05−0.08$ B$0BFY23FY24FY25
Mar 26: $0.0 B (null YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)
0.020.010.00−0.01−0.02$ B$0BMar 24Mar 25Mar 26
0.020.010.00−0.01−0.02$ B$0BMar 24Mar 25Mar 26
08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

BillionToOne, Inc.'s cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $0.0 B of operating cash against $0.0 B of profit. After $0.0 B of capital spending, $0.0 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.

FY25: operating cash of $0.0 B against reported profit of $0.0 B, leaving free cash of $0.0 B after $0.0 B of capital spending.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $0.0 B vs profit $0.0 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 3-year window, annual resolution.
Operating cashNet profitFree cash
0.030.00−0.03−0.05−0.08$ B$0B$0B$0BFY23FY24FY25
0.030.00−0.03−0.05−0.08$ B$0B$0B$0BFY23FY24FY25
Mar 26: operating cash $0.0 B = 100% of the quarter's profit Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 9 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
0.022101.2%0.014100.6%0.005100.0%−0.00499.4%−0.01298.8%$ B%$0B100%Mar 24Mar 25Mar 26
0.022101.2%0.014100.6%0.005100.0%−0.00499.4%−0.01298.8%$ B%$0B100%Mar 24Mar 25Mar 26

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

BillionToOne, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $0.0 B over the last 3 fiscal years.

FY25: capex $0.0 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
0.0110.0080.0050.0030.000$ B$0BFY23FY24FY25
0.0110.0080.0050.0030.000$ B$0BFY23FY24FY25
Mar 26: capex $0.0 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 9 quarters.
Capex (quarterly)Free cash
1.20.0120.60.0060.00.000−0.6−0.006−1.2−0.012$ B$ B$0B$0BMar 24Mar 25Mar 26
1.20.0120.60.0060.00.000−0.6−0.006−1.2−0.012$ B$ B$0B$0BMar 24Mar 25Mar 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

BillionToOne, Inc. earns a ROE of 2% in FY25. That is up from a trough of −233% in FY23. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 3.2% net margin on 0.49× asset turns.

FY25 ROE is 2%, recovered from a FY23 trough of −233% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY25): 3.2% net margin × 0.49× asset turns × 1.31× balance-sheet leverage ≈ 2.1% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

FY25: ROE 2% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 3-year window, dips included.
the climb back from FY23's −233%
ROEROIC (annual)
36%−36%−109%−181%−253%%2.1%9.1%FY23FY24FY25
36%−36%−109%−181%−253%%2.1%9.1%FY23FY24FY25
Mar 26: ROIC 17.9% (TTM) Trailing-twelve-month ROIC and ROE, per quarter, %. Last 9 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)
21%11%1.3%−8.2%−18%%17.9%5.6%Sep 23Mar 25Mar 26
21%11%1.3%−8.2%−18%%17.9%5.6%Sep 23Mar 25Mar 26
11 · Dividend

Dividend

BillionToOne, Inc. pays no dividend. Across the last 9 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

BillionToOne, Inc. does not currently pay a dividend. Across the last 9 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

BillionToOne, Inc. carries total debt of $0.1 B against shareholder equity of $0.5 B as of Mar 26, a debt-to-equity of 0.27 — effectively unlevered. On the annual view that ratio went from 5.00 in FY23 to 0.23 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of $0.1 B against shareholder equity of $0.5 B — a debt-to-equity of 0.27. On the annual view, debt-to-equity went from 5.00 (FY23) to 0.23 (FY25). The returns on this page are earned, not borrowed.

FY25: debt $0.1 B at 0.23× equity Total debt by fiscal year, $ B (bars); debt-to-equity, × (line). 3-year window.
Total debtDebt-to-equity
0.165.4×0.123.9×0.082.3×0.040.7×0.00−0.9×$ B×$0B0.23×FY23FY24FY25
0.165.4×0.123.9×0.082.3×0.040.7×0.00−0.9×$ B×$0B0.23×FY23FY24FY25
Mar 26: debt $0.1 B, debt-to-equity 0.27 Total debt per quarter, $ B (bars); debt-to-equity, × (line). Last 9 quarters.
Total debt (quarterly)Debt-to-equity
0.165.4×0.123.9×0.082.3×0.040.7×0.00−0.9×$ B×$0B0.27×Sep 23Mar 25Mar 26
0.165.4×0.123.9×0.082.3×0.040.7×0.00−0.9×$ B×$0B0.27×Sep 23Mar 25Mar 26
13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

8.2% of BillionToOne, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 2.9 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 8.2% of the float is sold short, and at typical trading volumes it would take about 2.9 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
8.2%
of the tradable float
Days to cover
2.9
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

BillionToOne, Inc.: the Z-score reads 14.08. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 14.08 sits well clear of the distress zone — the balance sheet is not the risk here.

The safety line in one sentence: the Z-score reads 14.08.

15 · Related companies · Diagnostics & Research
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Labcorp Holdings Inc.LH 62.1/100Mixed-positive evidence81% evidence BREAKING OUT 21.4/35 Revenue 6.4% · PAT 31.2% · OPM change 0.9 pp 83% evidence 14.9/25 ROCE 9.9% · OPM 12.2% 76% evidence 16.1/20 P/E 22.9× · PEG 0.69 65% evidence 9.7/20 RS sector -13.3% · RS bench 10% · 1Y 17%9 of 12 weeks ahead 100% evidence
Exact sum: 21.4 + 14.9 + 16.1 + 9.7 = 62.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Medpace Holdings, Inc.MEDP 61.9/100Thin evidence · provisional56% evidence BREAKING OUT 20.5/35 Revenue — · PAT — · OPM change -0.3 pp 39% evidence 21.3/25 ROCE 30.2% · OPM 20% 76% evidence 10.5/20 P/E 31× · PEG — 15% evidence 9.6/20 RS sector -13.4% · RS bench 9.2% · 1Y 23.6%9 of 12 weeks ahead 100% evidence
Exact sum: 20.5 + 21.3 + 10.5 + 9.6 = 61.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
3Agilent Technologies, Inc.A 58.6/100Mixed-positive evidence81% evidence BREAKING OUT 22.5/35 Revenue 9.1% · PAT 21.3% · OPM change 3.7 pp 83% evidence 15.4/25 ROCE 3.8% · OPM 21.7% 76% evidence 14.5/20 P/E 23.2× · PEG 1.01 65% evidence 6.2/20 RS sector -15% · RS bench 7.5% · 1Y 21.7%10 of 12 weeks ahead 100% evidence
Exact sum: 22.5 + 15.4 + 14.5 + 6.2 = 58.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Natera, Inc.NTRA 56.6/100Mixed-positive evidence61% evidence LEADER 24.7/35 Revenue 37.8% · PAT — · OPM change 10.1 pp 62% evidence 5.5/25 ROCE -4.4% · OPM -10.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 16.4/20 RS sector 12.2% · RS bench 40.5% · 1Y 90.7%12 of 12 weeks ahead 100% evidence
Exact sum: 24.7 + 5.5 + 10 + 16.4 = 56.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Adaptive Biotechnologies CorporationADPT 54.7/100Thin evidence · provisional53% evidence LEADER 20.9/35 Revenue — · PAT — · OPM change 29.3 pp 39% evidence 5.8/25 ROCE -3.3% · OPM -27.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 18.0/20 RS sector 18.8% · RS bench 48.4% · 1Y 107.1%12 of 12 weeks ahead 100% evidence
Exact sum: 20.9 + 5.8 + 10 + 18 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
6Quest Diagnostics IncorporatedDGX 54.5/100Mixed-positive evidence81% evidence BREAKING OUT 16.7/35 Revenue 9.9% · PAT 10.9% · OPM change -0.3 pp 83% evidence 16.4/25 ROCE 11.1% · OPM 15.2% 76% evidence 11.4/20 P/E 22.2× · PEG 1.75 65% evidence 10.0/20 RS sector -8.5% · RS bench 16% · 1Y 34.6%9 of 12 weeks ahead 100% evidence
Exact sum: 16.7 + 16.4 + 11.4 + 10 = 54.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7NeoGenomics, Inc.NEO 53.9/100Thin evidence · provisional56% evidence LEADER 20.2/35 Revenue — · PAT — · OPM change 6.8 pp 39% evidence 6.0/25 ROCE -0.8% · OPM -9.8% 76% evidence 9.0/20 P/E 134× · PEG — 15% evidence 18.7/20 RS sector 23.4% · RS bench 53.4% · 1Y 122.3%12 of 12 weeks ahead 100% evidence
Exact sum: 20.2 + 6 + 9 + 18.7 = 53.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
8Charles River Laboratories International, Inc.CRL 53.6/100Thin evidence · provisional51% evidence LEADER 17.4/35 Revenue 0.1% · PAT — · OPM change 4.4 pp 40% evidence 11.8/25 ROCE 1.8% · OPM 12% 57% evidence 8.8/20 P/E 427.2× · PEG — 15% evidence 15.6/20 RS sector 3.3% · RS bench 29.4% · 1Y 76%12 of 12 weeks ahead 100% evidence
Exact sum: 17.4 + 11.8 + 8.8 + 15.6 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
9Revvity, Inc.RVTY 53.3/100Thin evidence · provisional56% evidence LEADER 15.4/35 Revenue — · PAT — · OPM change -1.9 pp 39% evidence 11.5/25 ROCE 0.7% · OPM 10.7% 76% evidence 9.5/20 P/E 42.6× · PEG — 15% evidence 16.9/20 RS sector 6.2% · RS bench 34% · 1Y 68%12 of 12 weeks ahead 100% evidence
Exact sum: 15.4 + 11.5 + 9.5 + 16.9 = 53.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
10IQVIA Holdings Inc.IQV 52.7/100Mixed-positive evidence81% evidence LEADER 12.7/35 Revenue 8.2% · PAT 6% · OPM change -1 pp 83% evidence 13.2/25 ROCE 2.4% · OPM 11.6% 76% evidence 12.5/20 P/E 24× · PEG 1.44 65% evidence 14.3/20 RS sector -2.2% · RS bench 22.9% · 1Y 43.6%12 of 12 weeks ahead 100% evidence
Exact sum: 12.7 + 13.2 + 12.5 + 14.3 = 52.7 · Decision use: Price leads the evidence: RS versus the benchmark is 22.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
11IDEXX Laboratories, Inc.IDXX 52.0/100Mixed-positive evidence81% evidence ASLEEP 22.8/35 Revenue 12.8% · PAT 15.5% · OPM change 1.4 pp 83% evidence 20.9/25 ROCE 20% · OPM 35% 76% evidence 8.0/20 P/E 37× · PEG 2.01 65% evidence 0.3/20 RS sector -38.4% · RS bench -21.6% · 1Y -21.7%0 of 12 weeks ahead 100% evidence
Exact sum: 22.8 + 20.9 + 8 + 0.3 = 52 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -38.4% and the one-year return is -21.7%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
12Illumina, Inc.ILMN 49.5/100Mixed-negative evidence71% evidence LEADER 10.8/35 Revenue 4.9% · PAT -34.4% · OPM change 0.9 pp 83% evidence 13.8/25 ROCE 5.1% · OPM 21.1% 76% evidence 10.3/20 P/E 32.9× · PEG — 15% evidence 14.6/20 RS sector 17.3% · RS bench 47% · 1Y 122.8%12 of 12 weeks ahead 100% evidence
Exact sum: 10.8 + 13.8 + 10.3 + 14.6 = 49.5 · Decision use: Price leads the evidence: RS versus the benchmark is 47%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
13Sotera Health CompanySHC 48.3/100Thin evidence · provisional51% evidence LEADER 18.8/35 Revenue 7.3% · PAT 100% · OPM change 4.7 pp 40% evidence 13.6/25 ROCE 2.6% · OPM 27.1% 57% evidence 9.9/20 P/E 35× · PEG — 15% evidence 6.0/20 RS sector -14.7% · RS bench 7.8% · 1Y 23.7%11 of 12 weeks ahead 100% evidence
Exact sum: 18.8 + 13.6 + 9.9 + 6 = 48.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
14Mettler-Toledo International Inc.MTD 48.0/100Mixed-negative evidence81% evidence BREAKING OUT 17.4/35 Revenue 6.9% · PAT 9% · OPM change 2.8 pp 83% evidence 18.5/25 ROCE 12.9% · OPM 29.8% 76% evidence 7.6/20 P/E 28.8× · PEG 2.3 65% evidence 4.5/20 RS sector -23.2% · RS bench -2.6% · 1Y 8.9%8 of 12 weeks ahead 100% evidence
Exact sum: 17.4 + 18.5 + 7.6 + 4.5 = 48 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
15Thermo Fisher Scientific Inc.TMO 47.6/100Mixed-negative evidence81% evidence BREAKING OUT 14.6/35 Revenue 7.2% · PAT 6.1% · OPM change 0.9 pp 83% evidence 16.1/25 ROCE 9.1% · OPM 18.8% 76% evidence 5.7/20 P/E 27.4× · PEG 3.61 65% evidence 11.2/20 RS sector -11.1% · RS bench 12.2% · 1Y 35.2%9 of 12 weeks ahead 100% evidence
Exact sum: 14.6 + 16.1 + 5.7 + 11.2 = 47.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16Danaher CorporationDHR 45.4/100Mixed-negative evidence81% evidence BREAKING OUT 19.5/35 Revenue 4.6% · PAT 16.9% · OPM change 5.2 pp 83% evidence 13.3/25 ROCE 1.4% · OPM 18% 76% evidence 9.6/20 P/E 34.8× · PEG 1.76 65% evidence 3.0/20 RS sector -24.7% · RS bench -4.6% · 1Y 7.8%8 of 12 weeks ahead 100% evidence
Exact sum: 19.5 + 13.3 + 9.6 + 3 = 45.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17RadNet, Inc.RDNT 44.8/100Thin evidence · provisional51% evidence BREAKING OUT 17.8/35 Revenue 14.8% · PAT 100% · OPM change 0.9 pp 40% evidence 9.4/25 ROCE -0.8% · OPM -4.2% 57% evidence 8.6/20 P/E 1746× · PEG — 15% evidence 9.0/20 RS sector -17.9% · RS bench 3.8% · 1Y -0.9%10 of 12 weeks ahead 100% evidence
Exact sum: 17.8 + 9.4 + 8.6 + 9 = 44.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
18Qiagen N.V.QGEN 44.5/100Thin evidence · provisional56% evidence BREAKING OUT 16.3/35 Revenue 4.8% · PAT 100% · OPM change -6.8 pp 53% evidence 12.7/25 ROCE 1.6% · OPM 17.1% 57% evidence 11.4/20 P/E 20.9× · PEG — 15% evidence 4.1/20 RS sector -28.4% · RS bench -9.2% · 1Y -11.3%8 of 12 weeks ahead 100% evidence
Exact sum: 16.3 + 12.7 + 11.4 + 4.1 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
19Guardant Health, Inc.GH 43.1/100Thin evidence · provisional53% evidence LEADER 16.6/35 Revenue — · PAT — · OPM change 14.4 pp 39% evidence 4.3/25 ROCE -9.7% · OPM -40.2% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 12.2/20 RS sector 17.1% · RS bench 46.1% · 1Y 195.7%12 of 12 weeks ahead 100% evidence
Exact sum: 16.6 + 4.3 + 10 + 12.2 = 43.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
20Veracyte, Inc.VCYT 41.5/100Thin evidence · provisional56% evidence ASLEEP 20.5/35 Revenue — · PAT — · OPM change 13.8 pp 39% evidence 11.0/25 ROCE 1.7% · OPM 16.3% 76% evidence 9.7/20 P/E 41.7× · PEG — 15% evidence 0.3/20 RS sector -30.8% · RS bench -12.6% · 1Y 12.9%6 of 12 weeks ahead 100% evidence
Exact sum: 20.5 + 11 + 9.7 + 0.3 = 41.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
21ICON Public Limited CompanyICLR 41.5/100Thin evidence · provisional56% evidence BREAKING OUT 14.5/35 Revenue — · PAT — · OPM change -2.8 pp 39% evidence 10.8/25 ROCE 1% · OPM 8.5% 76% evidence 8.9/20 P/E 310.2× · PEG — 15% evidence 7.3/20 RS sector -15% · RS bench 6.8% · 1Y 0%12 of 12 weeks ahead 100% evidence
Exact sum: 14.5 + 10.8 + 8.9 + 7.3 = 41.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
22GeneDx Holdings Corp.WGS 37.7/100Thin evidence · provisional51% evidence BREAKING OUT 14.5/35 Revenue 33.8% · PAT — · OPM change -51 pp 40% evidence 6.2/25 ROCE -14.4% · OPM -56.2% 57% evidence 8.5/20 P/E 2693.5× · PEG — 15% evidence 8.5/20 RS sector -22% · RS bench -1.9% · 1Y -24.8%7 of 12 weeks ahead 100% evidence
Exact sum: 14.5 + 6.2 + 8.5 + 8.5 = 37.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
23Waters CorporationWAT 36.0/100Thin evidence · provisional58% evidence LEADER 11.8/35 Revenue — · PAT — · OPM change -29.2 pp 45% evidence 8.9/25 ROCE -0.7% · OPM -5.2% 76% evidence 9.2/20 P/E 94.6× · PEG — 15% evidence 6.1/20 RS sector -13.8% · RS bench 8.9% · 1Y 39.1%12 of 12 weeks ahead 100% evidence
Exact sum: 11.8 + 8.9 + 9.2 + 6.1 = 36 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
24BillionToOne, Inc.this pageBLLN 54.6/100Thin evidence · provisional31% evidence ASLEEP 23.0/35 Revenue 99.4% · PAT — · OPM change 20.4 pp 40% evidence 12.3/25 ROCE 3.9% · OPM 16.5% 57% evidence 9.3/20 P/E 60.9× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —7 of 12 weeks ahead 0% evidence
Exact sum: 23 + 12.3 + 9.3 + 10 = 54.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
25CareDx, Inc.CDNA 48.8/100Thin evidence · provisional50% evidence LEADER 15.8/35 Revenue — · PAT — · OPM change 16.8 pp 39% evidence 4.8/25 ROCE -28.5% · OPM 1% 76% evidence 11.5/20 P/E 13.8× · PEG — 15% evidence 16.7/20 RS sector 67.7% · RS bench 106.8% · 1Y 267%12 of 12 weeks ahead 70% evidence
Exact sum: 15.8 + 4.8 + 11.5 + 16.7 = 48.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
26Twist Bioscience CorporationTWST 48.5/100Thin evidence · provisional48% evidence LEADER 17.2/35 Revenue 17.8% · PAT — · OPM change 3.4 pp 40% evidence 6.7/25 ROCE -8.5% · OPM -41.4% 57% evidence 10.0/20 P/E — · PEG — 0% evidence 14.6/20 RS sector 79.4% · RS bench 121.5% · 1Y 413%12 of 12 weeks ahead 100% evidence
Exact sum: 17.2 + 6.7 + 10 + 14.6 = 48.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
27OPKO Health, Inc.OPK 47.3/100Thin evidence · provisional50% evidence TURNING 20.3/35 Revenue — · PAT — · OPM change 3.7 pp 39% evidence 7.2/25 ROCE -0.4% · OPM -41.1% 76% evidence 10.2/20 P/E 33.2× · PEG — 15% evidence 9.6/20 RS sector -10.7% · RS bench 13.2% · 1Y 11%9 of 12 weeks ahead 70% evidence
Exact sum: 20.3 + 7.2 + 10.2 + 9.6 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
28Castle Biosciences, Inc.CSTL 45.0/100Thin evidence · provisional50% evidence BREAKING OUT 18.5/35 Revenue — · PAT — · OPM change 9.7 pp 39% evidence 7.2/25 ROCE -0.6% · OPM -22% 76% evidence 9.4/20 P/E 43× · PEG — 15% evidence 9.9/20 RS sector -9.2% · RS bench 13.9% · 1Y 45.4%8 of 12 weeks ahead 70% evidence
Exact sum: 18.5 + 7.2 + 9.4 + 9.9 = 45 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
29Personalis, Inc.PSNL 43.2/100Thin evidence · provisional42% evidence LEADER 10.9/35 Revenue -27.6% · PAT — · OPM change -122 pp 40% evidence 5.9/25 ROCE -12.1% · OPM -207.9% 57% evidence 10.0/20 P/E — · PEG — 0% evidence 16.4/20 RS sector 24.5% · RS bench 54.1% · 1Y 164.1%12 of 12 weeks ahead 70% evidence
Exact sum: 10.9 + 5.9 + 10 + 16.4 = 43.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
30GRAIL, Inc.GRAL 38.3/100Thin evidence · provisional48% evidence LEADER 20.0/35 Revenue 19.9% · PAT — · OPM change 149.6 pp 40% evidence 6.4/25 ROCE -4.9% · OPM -332.9% 57% evidence 10.0/20 P/E — · PEG — 0% evidence 1.9/20 RS sector -23.6% · RS bench -4.1% · 1Y 80.3%12 of 12 weeks ahead 100% evidence
Exact sum: 20 + 6.4 + 10 + 1.9 = 38.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is BillionToOne, Inc.'s stock price today?

BillionToOne, Inc. trades at $104, +3.6% over the past year. The company is valued at $5.0 B. The stock sits at 50% of its 52-week range of $69–$139, +9.2% versus its 200-day average. Against the S&P 500 it has been behind on a trailing-13-week view for 4 weeks. — as of 17 September 2026.

What were BillionToOne, Inc.'s latest quarterly results?

BillionToOne, Inc. reported revenue of $0.1 B and net profit of $0.0 B for the Mar 26 quarter. Earnings per share were $0.34. The operating margin was 18.2%, 18.2 pp higher than a year earlier. — as of 17 September 2026.

What is BillionToOne, Inc.'s revenue?

BillionToOne, Inc. reported revenue of $0.1 B in the Mar 26 quarter, +83.3% year on year. For the full FY25 fiscal year, revenue was $0.3 B (+106.7%). Over the last 2 years revenue compounded at 110.4% a year. — as of 17 September 2026.

What is BillionToOne, Inc.'s profit?

BillionToOne, Inc. earned $0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $0.0 B. The operating margin ran 18.2% in the latest quarter. — as of 17 September 2026.

What is BillionToOne, Inc.'s market cap?

BillionToOne, Inc.'s market capitalisation is $5.0 B at a stock price of $104. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.

Does BillionToOne, Inc. pay a dividend?

No — BillionToOne, Inc. has declared no dividend per share in any of its last 9 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 17 September 2026.

How is BillionToOne, Inc. performing?

BillionToOne, Inc.'s latest readings are below. Against the S&P 500 it has been behind on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 17 September 2026.

Is BillionToOne, Inc. beating the market?

Not lately — on a trailing-13-week view BillionToOne, Inc. is currently behind the S&P 500 (4 weeks and counting; last ahead the week of 2026-08-21), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 11 months the stock moved +4% against the S&P 500's +12% — behind the index over the full window. — as of 17 September 2026.

Will BillionToOne, Inc.'s stock price go up?

This page publishes no price forecast for BillionToOne, Inc. What it measures instead: the stock price is $104. Direction is not something this site claims to know. — as of 17 September 2026.

Is the market betting against BillionToOne, Inc.?

Somewhat — short interest is 8.2% of BillionToOne, Inc.'s tradable float, about 2.9 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.

Does BillionToOne, Inc. have too much debt?

No — BillionToOne, Inc.'s debt-to-equity is 0.27. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 17 September 2026.

What is BillionToOne, Inc.'s capex?

BillionToOne, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 17 September 2026.

What is BillionToOne, Inc.'s cash flow?

BillionToOne, Inc. generated $0.0 B of operating cash flow in FY25 and $0.0 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.0 B, so operating cash ran ahead of profit. — as of 17 September 2026.

How financially safe is BillionToOne, Inc.?

On the balance sheet, the Z-score reads 14.08 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.

Where is BillionToOne, Inc. in its business cycle?

BillionToOne, Inc.'s FY25 operating margin was 6.5%, against a 3-year band of −100.0%–6.5%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 18.2%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.

What could break the BillionToOne, Inc. story?

Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.

Is BillionToOne, Inc. a stock worth studying right now?

This is not investment advice. The machine read: BillionToOne, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.

Sector Alpha — machine-written from the numbers · Data as of 2026-09-17. Every chart on this page is drawn by deterministic code from the raw series — no forecasts, no price opinions, and nothing here is investment advice.

Not SEBI Registered !! Not Investment advice !!

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI